Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS

Behavioural Brain Research

Volumn 211, Issue 1, 2010, Pages 125-131

  Woo, Dong Cheol ^a   Lee, Sung Ho ^b   Lee, Do Wan ^a   Kim, Sang Young ^a   Kim, Goo Young ^a   Rhim, Hyang Shuk ^a   Choi, Chi Bong ^c   Kim, Hwi Yool ^b   Lee, Chang Uk ^a   Choe, Bo Young ^a  

^a The Catholic University of Korea   (South Korea)

^b Konkuk University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Alzheimer disease; APP PS1 mouse; High resolution magic angle spinning; Object recognition test

Indexed keywords

N ACETYLASPARTIC ACID;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TASK PERFORMANCE; TEMPORAL CORTEX; THALAMUS;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN MAPPING; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MATCHED-PAIR ANALYSIS; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; PRESENILIN-1; RECEPTORS, CELL SURFACE; RECOGNITION (PSYCHOLOGY); SPECTRUM ANALYSIS; SPIN LABELS; STATISTICS, NONPARAMETRIC;

EID: 77952320439     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.03.026     Document Type: Article

References (48)

1. Cheng L.L., Ma M.J., Becerra L., Ptak T., Tracey I., Lackner A., et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997, 94:6408-6413.
2. Cheng L.L., Chang I.W., Louis I.G., Gonzalez R.G. Correlation of high resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998, 58:1825-1832.
3. Cheng L.L., Newell K., Mallory A.E., Hyman B.T., Gonzalez R.G. Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 2002, 20:527-533.
4. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001, 276:21562-21570.
5. Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem Res 2003, 28:1029-1034.
6. Dedeoglu A., Choi J.-K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004, 1012:60-65.
7. Dominguez-del-Toro E., Rodriguez-Moreno A., Porras-Garcia E., Sanchez-Campusano R., Blanchard V., Laville M., et al. An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease. Eur J Neurosci 2004, 20:1945-1952.
8. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-Tur J., et al. Increased amyloid-β 42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
9. Eilers M., Reeves P.J., Ying W., Khorana H.G., Smith S.O. Magic angle spinning NMR of the protonated retinylidene Schiff base nitrogen in rhodopsin: Expression of 15N-lysine- and 13C-glycine-labeled opsin in a stable cell line. Proc Natl Acad Sci 1999, 96:487-492.
10. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995, 373:523-527.
11. Gazdzinski S., Kornak J., Weiner M.W., Meyerhoff D.J. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 2008, 63:652-657.
12. Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006, 100:328-335.
13. Gomez-Isla T., Price J.L., Mckeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease. J Neurosci 1996, 16:4491-4500.
14. Griffith H.R., den Hollander J.A., Stewart C.C., Evanochko W.T., Buchthal S.D., Harrell L.E., et al. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed 2007, 20:709-716.
15. Gruart A., Lopez-Ramos J.C., Munoz M.D., Delgado-Garcia J.M. Aged wild-type and APP, PS1, and APP+PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load. Neurobiol Dis 2008, 30:439-450.
16. Hattori N., Abe K., Sakoda S., Swada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2001, 13:183-186.
17. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
18. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., et al. Cognitive correlates of Aβ deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 2004, 1017:130-136.
19. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, A elevation and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
20. Huang W., Alexander G.E., Daly E.M., Shetty H.U., Krasuski J.S., Rapoport S.I., et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's Syndrome: A 1H MRS study. Am J Psychiatry 1999, 156:1879-1886.
21. Jensen M.T., Mottin M.D., Cracchiolo J.R., Leighty R.E., Arendash G.W. Lifelong immunisation with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005, 130:667-684.
22. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., et al. Proton MR Spectroscopy in Mild Cognitive Impairment and Alzheimer Disease: Comparison of 1.5 and 3 T. Am J Neuroradiol 2003, 24:843-849.
23. Kantarci K., Knopman D.S., Dickson D.W., Parisi J.E., Whitwell J.L., Weigand S.D., et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008, 248:210-220.
24. Kawasumi M., Chiba T., Yamada M., Miyamac-Kaneko M., Matsuoka M., Nakahara J., et al. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice. Eur J Neurosci 2004, 19:2826-2838.
25. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP (SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 1999, 103:145-162.
26. Lee K.W., Lee S.H., Kim H., Song J.S., Yang S.D., Paik S.G., et al. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 2004, 76:572-580.
27. Lucas D.R., Newhouse J.P. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthal 1957, 58:193-201.
28. Marjanska M., Curran G.L., Wengenack T.M., Henry P.-G., Bliss R.L., Poduslo J.F., et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci 2005, 102:11906-11910.
29. McLaurin J., Golomb R., Jurewicz A., Antel J.P., Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit Aβ-induced toxicity. J Biol Chem 2000, 275:18495-18502.
30. McLaurin J., Franklin T., Chakrabartty A., Fraser P.E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-β fibril growth and arrest. J Mol Biol 1998, 278:183-194.
31. Mehta V., Namboodiri M.A.A. N-Acetylaspartate as an acetyl source in the nervous system. Mol Brain Res 1995, 31:151-157.
32. Minkeviciene R., Banerjee P., Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004, 311:677-682.
33. Oberg J., Spenger C., Wang F.-H., Andersson A., Westman E., Skoglund P., et al. Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 2008, 29:1423-1433.
34. Ognibene E., Middei S., Daniele S., Adriani W., Ghirardi O., Caprioli A., et al. Aspects of spatial memory and behavioural disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 2005, 156:225-232.
35. Pennanen C., Kivipelto M., Tuomainen S., Hartikainen P., Hanninen T., Laakso M.P., et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004, 25:303-310.
36. Pugh P.L., Richardson J.C., Bate S.T., Upton N., Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 2007, 178:18-28.
37. Richards J.G., Higgins G.A., Ouagazzal A.-M., Ozmen L., Kew J.N.C., Bohrmann B., et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003, 23:8989-9003.
38. Siger M., Schuff N., Zhu X., Miller B.L., Weiner M.W. Regional myo-inositol concentration in mild cognitive impairment using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 2009, 23:57-62.
39. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci 1997, 94:13287-13292.
40. Swanson M.G., Zektzer A.S., Tabatabai Z.L., Simko J., Jarso S., Keshari K.R., et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006, 55:1257-1264.
41. Tate A.R., Foxall P.J.D., Moka D., Spraul M., Nicholson J.K., Lindon J.C. Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of 1H magic angle spinning (MAS) NMR spectra. NMR Biomed 2000, 13:64-71.
42. Touma C., Ambree O., Gortz N., Keyvani K., Lewejohann L., Palme R., et al. Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2004, 25:893-904.
43. Tsang T.M., Griffin J.L., Haselden J., Fish C., Holmes E. Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. Magn Reson Med 2005, 53:1018-1024.
44. van Groen T., Kiliaan A.J., Kadish I. Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 2006, 23:653-662.
45. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J.G., Ozmen L., et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 2005, 18:32-39.
46. Wang H., Ferguson G.D., Pineda V.V., Cundiff P.E., Storm D.R. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat Neurosci 2004, 7:635-642.
47. Wengenack T.M., Whelan S., Curran G.L., Duff K.E., Poduslo J.F. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 2000, 101:939-944.
48. Xu Y., Jack C.R., O'Brien P.C., Kokmen E., Smith G.E., Ivnik R.J., et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000, 54:1760-1767.